Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 3.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 0.93 | 1.93 |
NAV | ₹17.30 | ₹40.74 |
Fund Started | 25 Nov 2022 | 12 Nov 2018 |
Fund Size | ₹74.96 Cr | ₹3094.08 Cr |
Exit Load | - | Exit load of 0.50% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 53.41% | 58.33% |
3 Year | - | 21.75% |
5 Year | - | 31.03% |
1 Year
3 Year
5 Year
Equity | 99.91% | 96.74% |
Cash | 0.09% | 3.26% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 25.51% |
Cipla Ltd. | 11.15% |
Dr. Reddy's Laboratories Ltd. | 10.10% |
Divi's Laboratories Ltd. | 8.47% |
Lupin Ltd. | 6.47% |
Aurobindo Pharma Ltd. | 5.01% |
Alkem Laboratories Ltd. | 3.88% |
Torrent Pharmaceuticals Ltd. | 3.85% |
Zydus Lifesciences Ltd. | 3.28% |
Glenmark Pharmaceuticals Ltd. | 3.09% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.68% |
Suven Pharmaceuticals Ltd. | 9.80% |
Ipca Laboratories Ltd. | 7.77% |
Lupin Ltd. | 7.74% |
Cipla Ltd. | 7.41% |
Alembic Pharmaceuticals Ltd. | 5.55% |
Globus Medical Inc | 5.21% |
Illumina Inc. (USA) | 4.92% |
Apollo Hospitals Enterprise Ltd. | 4.33% |
Concord Biotech Ltd. | 3.84% |
Name | Kayzad Eghlim | Jay Kothari |
Start Date | 03 Dec 2021 | 16 Mar 2018 |
Name
Start Date
Description | The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 25 Nov 2022 | 12 Nov 2018 |
Description
Launch Date